Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

NCT00498407 is registered in ClinicalTrials.gov with Clavis Pharma as lead sponsor.

NCT NCT00498407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00498407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Lead sponsor
Clavis Pharma
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
December 31, 2008
Enrollment
16 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer, colorectal cancer